Osaka Soda Co (4046) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
18 May, 2026Executive summary
Net sales for the nine months ended December 31, 2025, decreased 1.3% year-over-year to ¥73,688 million, while operating profit rose 21.6% to ¥12,937 million and profit attributable to owners of parent increased 34.0% to ¥10,640 million.
Comprehensive income nearly doubled year-over-year, reaching ¥14,725 million, reflecting strong profit growth and improved other comprehensive income.
The group advanced its medium-term management plan, focusing on strengthening existing businesses, new product creation, and sustainability management.
Major capital investments were made to expand production capacity in healthcare and basic chemicals, with further expansions planned through 2028.
Financial highlights
Operating profit increased 21.6% year-over-year to ¥12,937 million; ordinary profit rose 24.9% to ¥14,619 million.
Profit attributable to owners of parent grew 34.0% year-over-year to ¥10,640 million.
Basic earnings per share for the nine months was ¥84.92, up from ¥62.59 year-over-year (adjusted for stock split).
Comprehensive income increased 90.9% year-over-year to ¥14,725 million.
Net assets rose 6.4% since March 31, 2025, to ¥122,952 million.
Outlook and guidance
Full-year forecast for FY ending March 2026 remains unchanged: net sales ¥102,000 million (+5.8% YoY), operating profit ¥17,300 million (+30.6%), ordinary profit ¥18,700 million (+32.1%), profit attributable to owners of parent ¥13,500 million (+30.7%), EPS ¥108.28.
No revisions to previously announced forecasts; any changes will be disclosed as appropriate.
Latest events from Osaka Soda Co
- Operating profit jumped 41.7% on 7.6% higher sales, led by healthcare and functional chemicals.4046
Q2 202518 May 2026 - Profits and sales rose on strong healthcare and chemicals demand; stock split set for October.4046
Q1 202518 May 2026 - Profits surged on healthcare growth and supply recovery, with record highs forecast for FY2025 and FY2026.4046
Q4 202518 May 2026 - Profits surged on strong healthcare demand and supply recovery; full-year outlook maintained.4046
Q3 202518 May 2026 - Profits rose sharply despite lower sales, with upward guidance and enhanced shareholder returns.4046
Q2 202618 May 2026 - First-quarter profit rose 9.4% year-on-year, driven by healthcare and basic chemicals growth.4046
Q1 202618 May 2026 - Record profits and sales driven by Basic chemicals and Healthcare, with robust cash flow and new growth plans.4046
Q4 202618 May 2026